Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lebanon Sci-Tech Weekly.
Press releases published on August 18, 2025
Global Clinical Decision Support Systems Market to Reach USD 3.89 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Accelerating adoption of healthcare IT, rising focus on patient safety, and government-backed digital health initiatives reshape global care delivery The global clinical decision support systems (CDSS) …
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer
ROCKVILLE, Md., Aug. 18, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the appointment of Shiniu Wei as Chief Financial Officer (CFO). Mr. Wei joins OncoC4 with nearly 20 …
Aditude Appoints Anthony Gonsalves as First Chief Revenue Officer
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aditude, a leading technology company, today announced the appointment of Anthony Gonsalves as its first Chief Revenue Officer (CRO). Gonsalves joins Aditude from JWP Connatix, where he served as Senior Vice …
Nuvini Group Unveils New Leadership Incentive Plan, Underscoring Commitment to Shareholders
~ Strengthens Leadership Incentives and Alignment Around Long-Term Growth Objectives and Disciplined Capital Allocation ~ NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading technology …
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company’s Chief Financial Officer, effective immediately. …
LIXTE Biotechnology Holdings Provides Corporate Update
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scientific …
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025 Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA …
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene …
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed …
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet. Entered into an Asset Purchase Agreement with …
Treatment.com AI Inc. to Rebrand as Rocket Doctor AI Inc., Aligning Business with Evolving Product Portfolio and Market Strategy
New name to take effect and begin trading on the Canadian Securities Exchange under the new ticker AIDR effective August 21, 2025 Rebrand unites the company’s proprietary Global Library of Medicine (GLM) with Rocket Doctor Inc’s leading digital health …
Rezolve Ai Celebrates One Year Anniversary of Nasdaq Listing with Explosive Growth, $70M+ ARR, and Global Expansion
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), the company reinventing retail through real-time AI-driven consumer engagement, today celebrates a game-changing first year as a public company capping 12 months of growth, major …
Applied Digital to Break Ground on $3 Billion Polaris Forge 2 Campus in September 2025, Expanding North Dakota’s Role as a National AI Infrastructure Leader
DALLAS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) announced today it plans to break ground in September 2025 on Polaris Forge 2, a $3 billion, 280-megawatt (MW) AI Factory near Harwood, North Dakota. Designed with the …
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed …
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients Treated with 1.5mg Dose (p=0.0094) -- -- …
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety …
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the …
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA …
Theratechnologies annonce le dépôt des documents relatifs à l’assemblée extraordinaire et l’obtention d’une ordonnance provisoire concernant son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
Les actionnaires pourraient recevoir une prime en espèces considérable et attrayante puisque le prix d’achat de 3,01 $ US, assorti d’un droit conditionnel à la valeur représentant des paiements supplémentaires totaux pouvant atteindre 1,19 $ US par action, …
Bitdeer Reports Unaudited Financial Results for the Second Quarter of 2025
- Q2 revenue of $155.6 million up 56.8% year-over-year and 121.9% sequentially - $69.5 million revenue from external sale of SEALMINER A2s - On track to achieve 40 EH/s of self-mining by end of October and exceed 40 EH/s by year-end - Entered into advanced …